EDIT
Editas Medicine Inc.
$2.74
$0.00(0.00%)
40
Overall
40
Value
45
Tech
36
Quality
Market Cap
$221.84M
Volume
1.54M
52W Range
$0.91 - $4.54
Target Price
$5.19
Company Overview
| Mkt Cap | $221.84M | Price | $2.74 |
| Volume | 1.54M | Change | +0.00% |
| P/E Ratio | -0.9 | Open | $2.71 |
| Revenue | $32.3M | Prev Close | $2.74 |
| Net Income | $-237.1M | 52W Range | $0.91 - $4.54 |
| Div Yield | N/A | Target | $5.19 |
| Overall | 40 | Value | 40 |
| Quality | 36 | Technical | 45 |
No chart data available
About Editas Medicine Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest News
JonesTrading Sticks to Their Buy Rating for Editas Medicine (EDIT)
TipRanks Auto-Generated Intelligence Newsdesk•2 days ago
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
TipRanks Auto-Generated Newsdesk•12 days ago
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)
Brian Anderson•22 days ago
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH)
Christine Brown•23 days ago
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EDIT | $2.74 | 0% | 1.54M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |